

## Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer

### Coding Specifications

Codes required to document patient has breast cancer and a visit occurred:

An ICD-9 diagnosis code for breast cancer and a CPT E/M service code are required to identify patients to be included in this measure.

#### Breast cancer ICD-9 diagnosis codes

- 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 (malignant neoplasm of female breast)

AND

#### CPT E/M service codes

- 99201, 99202, 99203, 99204, 99205 (office-new patient),
- 99212, 99213, 99214, 99215 (office-established patient)

Quality codes for this measure (at least one of the following for every eligible patient):

#### CPT II Code descriptors

(Data Collection sheet should be used to determine appropriate combination of codes.)

- **CPT II 3315F:** Estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer
- **CPT II 3316F:** Estrogen receptor (ER) and progesterone receptor (PR) negative breast cancer
- **CPT II 3305F:** AJCC Cancer Stage IC, documented<sup>1</sup> (Use 3305F to report Stage T1c breast cancer)
- **CPT II 3306F:** AJCC Cancer Stage IIA, documented

- **CPT II 3307F:** AJCC Cancer Stage IIB, documented
- **CPT II 3309F:** AJCC Cancer Stage IIIA, documented
- **CPT II 3310F:** AJCC Cancer Stage IIIB, documented
- **CPT II 3311F:** AJCC Cancer Stage IIIC, documented
- **CPT II 3302F:** AJCC Cancer Stage 0, documented
- **CPT II 3303F:** AJCC Cancer Stage IA, documented<sup>2</sup> (Use 3303F to report Stage T1mic, T1a, and T1b breast cancer)
- **CPT II 3312F:** AJCC Cancer Stage IV, documented
- **CPT II 3305F–8P:** No documentation of cancer stage
- **CPT II 3316F–8P:** No documentation of estrogen receptor (ER) and progesterone receptor (PR) status
- **CPT II 4179F:** Tamoxifen or aromatase inhibitor (AI) prescribed
- **CPT II 4179F–1P:** Documentation of medical reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient's disease has progressed to metastatic; patient is receiving a gonadotropin-releasing hormone analogue, patient has received oophorectomy, patient is receiving radiation or chemotherapy, patient's diagnosis date was ≥ 5 years from reporting date)
- **CPT II 4179F–2P:** Documentation of patient reason(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient refusal)
- **CPT II 4179F–3P:** Documentations of system reasons(s) for not prescribing tamoxifen or aromatase inhibitor (eg, patient is currently enrolled in a clinical trial)
- **CPT II 4179F–8P:** Tamoxifen or aromatase inhibitor **not** prescribed, reason not otherwise specified

<sup>1</sup>Report 3305F for Stage T1c Breast Cancer-Tumor more than 1 cm but not more than 2 cm in greatest dimension.

<sup>2</sup>Report 3303F for the following Stage I Breast Cancers:

- T1mic** — Microinvasion 0.1 cm or less in greatest dimension
- T1a** — Tumor more than 0.1 cm but not more than 0.5 cm in greatest dimension
- T1b** — Tumor more than 0.5 cm but not more than 1 cm in greatest dimension

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

CPT® contained in the Measures specifications is copyright 2007 American Medical Association.

PQRI 2008 Measure 71, Effective Date 01/01/2008

© 2007 American Medical Association, American Society of Clinical Oncology, and National Comprehensive Cancer Network. All Rights Reserved.

CPT® Copyright 2007 American Medical Association.